Profil
David DeLong joined Allos in August 2002 as Vice President, Sales and Marketing.
Mr. DeLong, a 21-year biomedical veteran, joined Allos from the DevStrat Group, a biomedical consulting and commercial management company that he founded.
Before forming his own consulting company, Mr. DeLong was Vice President of Sales and Commercial Operations at SEQUUS Pharmaceuticals, Inc., where he was responsible for the design, implementation and management of the U.S.
sales operation in support of the launch of DOXIL® chemotherapeutic product.
Prior to that, as international marketing director, he was responsible for global market planning and distribution of AMPHOCIL®, an injectable antifungal product.
Mr. DeLong also served as Senior Product Manager at Genentech Incorporated, where he had brand management responsibilities for the ACTIVASE® recombinant tPA product line.
Mr. DeLong has a B.S.
in Economics from the University of Kentucky.
Anciens postes connus de David A. DeLong
| Sociétés | Poste | Fin |
|---|---|---|
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Sales & Marketing | 16/02/2007 |
Formation de David A. DeLong
| University of Kentucky | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
